Clinical guideline highlights for the hospitalist: Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy
Saurabh Deepak Chitnis, Amir Mortazavi
Abstract
GUIDELINE TITLE: Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update RELEASE DATE: November 1, 2021 PRIOR VERSION(S): February 14, 2018 DEVELOPER: American Society of Clinical Oncology FUNDING SOURCE: American Society of Clinical Oncology TARGET POPULATION: Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone.
Topics & Concepts
MedicineGuidelineAdverse effectImmune checkpointClinical OncologyOncologyBlockadeInternal medicineImmune systemPopulationIntensive care medicineCancerImmunotherapyImmunologyPathologyEnvironmental healthReceptorCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesNeutropenia and Cancer Infections